Today: 29 April 2026
Browse Category

NASDAQ:DGNX 24 September 2025 - 25 November 2025

Diagnex Inc. (DGNX) Stock Skyrockets in 2025 – An Epic ESG Tech Rally and What’s Next

Diginex (DGNX) Stock Skyrockets 3,000% – Latest News, Expert Insights & 2025 Outlook

Diginex Limited (NASDAQ: DGNX) shares surged over 3,000% in 2025, rising from $0.45 to around $20 and pushing its market cap to $3–4 billion despite just $2 million in annual revenue. The company completed a $13 million acquisition of Denmark’s Matter DK and announced new ESG software partnerships. Diginex also executed a 7-for-1 stock split and plans a $2 billion Resulticks takeover using mostly its own shares. Analyst coverage remains sparse and bearish.
7 October 2025
·
Diginex (DGNX) – The ESG Tech Stock Soaring in 2025: What Investors Need to Know

Diginex (DGNX) – The ESG Tech Stock Soaring in 2025: What Investors Need to Know

Diginex shares surged over 3,000% in 2025, closing near $16.50 after trading below $1 earlier in the year. The company’s market cap reached $3 billion despite 2025 revenues of just $2.04 million and a net loss of $5.21 million. Diginex provides ESG compliance software and went public in January 2025. The stock trades at over 1,400 times sales, reflecting investor bets on rapid growth.
4 October 2025
··
Diagnex Inc. (DGNX) Stock Skyrockets in 2025 – An Epic ESG Tech Rally and What’s Next

DGNX Stock Report – Why Diginex’s Growth Spree and ESG Focus Could Make or Break Your Portfolio in 2025

Diginex Limited (DGNX) last traded at $14.56 on Nasdaq, unchanged from the previous close, with 9,721 shares in volume on 2 Oct 2025. Market cap estimates range from $2.65 billion (Reuters) to $3.25 billion (StockAnalysis). The company completed an eight-for-one bonus share issue in September and announced deals to acquire Matter DK ApS and partner with iNEED in Indonesia. No Wall Street analyst coverage; AI ratings are mixed.
2 October 2025
··
Diagnex Inc. (DGNX) Stock Skyrockets in 2025 – An Epic ESG Tech Rally and What’s Next

Diagnex Inc. (DGNX) Stock Skyrockets in 2025 – An Epic ESG Tech Rally and What’s Next

Diagnex Inc. (NASDAQ: DGNX) stock surged after its January 2025 IPO, peaking near $19 in September following an 8-for-1 split, despite sharp volatility and daily swings of up to 15%. The company reported a 57% revenue jump to $2 million for the fiscal year, but net loss widened to $5.2 million. Diagnex announced plans to acquire Resulticks Group for $2 billion and Matter DK ApS for $13 million, both pending.
24 September 2025
··

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Cambridge, Massachusetts, April 29, 2026, 09:04 EDT Biogen Inc. cut its full-year profit outlook on Wednesday, taking some shine off a first-quarter earnings beat driven by stronger sales of its Alzheimer’s drug Leqembi and newer rare-disease medicines. The Cambridge, Massachusetts-based drugmaker now expects 2026 adjusted earnings of $14.25 to $15.25 a share, down $1 at both ends of its prior range. Biogen said the cut reflects acquired in-process research and development charges, meaning costs tied to buying or licensing drug programs that are still being developed and have not yet become commercial products. (marketscreener.com) The revision matters because Biogen is
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop